Costs of adalimumab versus infliximab as first-line biological therapy for luminal Crohn's disease.

Background And Aims: Randomised controlled trials demonstrate that the anti-tumour necrosis factor-α (anti-TNFα) therapies infliximab and adalimumab are effective in inducing remission and preventing relapse of Crohn's disease (CD). As few studies have compared costs and efficacy of these two drugs directly, we examined this issue.

Methods: Data were collected for patients receiving either drug as first-line anti-TNFα for CD.